Skip to main content
Premium Trial:

Request an Annual Quote

Aldevron to Manufacture, Distribute IDT-Patented Cas9 Variant

NEW YORK (GenomeWeb) – Nucleic acids production company Aldevron said today it has signed a licensing agreement with Integrated DNA Technologies to manufacture and distribute an S. pyogenes Cas9 variant patented by IDT — known as SpyFi Cas9 Nuclease — for research, clinical, and commercial uses.

"A significant amount of development effort went into making an S. pyogenes HiFi Cas9 mutant that worked in ribonucleoprotein formats, compatible with use in ex vivo clinical protocols," IDT CSO Mark Behlke said in a statement. "We are excited to expand our collaboration with Aldevron to make available a full [good manufacturing practices] version of this novel protein and to better serve the biomedical community, in addition to our traditional research markets."

SpyFi Cas9 was engineered to have fewer off-target effects than wild-type SpCas9 nuclease, according to Aldevron's website. When used in combination with effective guide, target site, and double-stranded DNA cutting strategies, SpyFi Cas9 is also expected to deliver greater editing efficiency and higher fidelity than the wild-type SpCas9.

Aldevron added it plans to have research-grade SpyFi Cas9 available for shipment in December 2017, and anticipates having clinical grade SpyFi Cas9 available in Q4 2018. 

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.